Latest fiscal year 2025 · computed deterministically from XBRL 10-K data · coverage 100%
In fiscal 2025, Lyell Immunopharma, Inc. reported revenue of $0M, down 41.0% year over year. Operating margin was -748344.4% and net margin -762355.6%, on a free-cash-flow margin of -418900.0% with capital expenditure at 2166.7% of revenue. Every figure is computed directly from LYEL's SEC XBRL 10-K filing — deterministic, with no estimates.
| Fiscal year | Revenue | Op margin | Net margin |
|---|---|---|---|
| FY2025 | $0M | -748344.4% | -762355.6% |
| FY2024 | $0M | -588123.0% | -562285.2% |
| FY2023 | $0M | -190006.2% | -180486.2% |
| FY2022 | $85M | -220.9% | -216.2% |
| FY2021 | $11M | -2016.7% | -2349.5% |
How does LYEL compare against its actual peer set?
A CompsDesk subscription covers unlimited benchmark packs on any covered company: up to 19 metrics (6 core guaranteed) × up to 5 fiscal years × up to 12 chosen peers, percentile placement, the subject's figures cited to their SEC tag, form and period with every company identified by its CIK, PDF-ready HTML + CSV, generated on demand.
Related in the same sector: AAWH · ABBV · ABCL · ABT · ABUS · ACAD
Source: SEC EDGAR XBRL (10-K filings), latest filed values. "n/a" = not disclosed under mapped tags — never estimated. Informational benchmarking, not investment advice. © CompsDesk / Sam Arora.